# US 2008/0287448 A1 · Diacyl indazole derivatives as lipase and phospholipase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287448 A1
- Document ID: US20080287448A1
- Status: Published application
- Kind: A1
- Application number: 12/099,337
- Filed: 2008-04-08
- Published: 2008-11-20
- Earliest claimed: 2005-10-12
- Assignees: Sanofi-Aventis
- Inventors: Gerhard Zoller; Stefan Petry; Gunter Muller; Hubert Heuer; Norbert Tennagels
- Web page: https://patentgrep.com/patent/US20080287448A1

## CPC

- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds as pharmaceutical products.

## Claims

### Claim 1

A compound of the formulae I or II:
wherein
X is identically or differently ═C(—R)— or ═N—, where not more than two X are ═N—;
R is identically or differently hydrogen, halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy-(C1-C3)-alkylene, (C1-C3)-haloalkyl, hydroxy, (C1-C6)-alkyl-mercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, mono-(C1-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, COOR3, cyano, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylsulfinyl, aminosulfonyl, nitro, pentafluorosulfanyl, phenyl, heterocycle, phenoxy, O-heterocycle, CO—NR6R7, O—CO—NR6R7, O—CO—(C1-C6)-alkylene-CO—O—(C1-C6)-alkyl, O—CO—(C1-C6)-alkylene-CO—OH, O—CO—(C1-C6)-alkylene-CO—NR6R7 or unsubstituted or mono- or poly-F-substituted (C1-C6)-alkyloxy;
R1 is identically or differently (C5-C16)-alkyl, (C3-C12)-cycloalkyl, Y-aryl, Y-heterocycle or bicycle, where cycloalkyl, aryl, heterocycle or bicycle are optionally substituted one or more times by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxy, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, mono-(C1-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (C1-C6)-alkyloxycarbonyl, (C1-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (C1-C6)-alkylsulfonyl, aminosulfonyl, and nitro;
Y is (C1-C3)-alkyl, which is optionally substituted one or more times by halogen, (C1-C3)-alkyl, hydroxy or trifluoromethyl;
R2 is hydrogen; or
R1 and R2 together with the nitrogen atom carrying them form a monocyclic, saturated or partly unsaturated 4- to 7-membered ring system or a bicyclic saturated or partly unsaturated 8- to 14-membered ring system whose individual members of the ring systems are optionally replaced by one to three atoms or atomic groups from the series —CHR4-, —CR4R5-, —(C═R4)-, —NR4-, —C(═O)—, —O—, —S—, —SO—, —SO2—, with the proviso that two units from the series —O—, —S—, —SO—, —SO2— are not adjacent to each other;
R3 is hydrogen, (C1-C6)-alkyl or benzyl;
R4, R5 are identically or differently (C1-C6)-alkyl, halogen, trifluoromethyl, phenyl, heterocycle, COOR3 or (C3-C12)-cycloalkyl; and
R6, R7 are identically or differently hydrogen, (C1-C6)-alkyl, phenyl, benzyl or (C3-C12)-cycloalkyl; or
a tautomer thereof or a physiologically tolerated salt thereof,
with the proviso that not more than one R is phenyl or heterocycle.

### Claim 2 (depends on 1)

The compound of the formulae I or II as claimed in claim 1, wherein:
X is identically or differently ═C(—R)— or ═N—, where not more than one X is ═N—;
R is identically or differently hydrogen, halogen, (C1-C6)-alkyl, hydroxy, (C1-C3)-alkyloxy, amino, COOR3, trifluoromethyl, (C1-C6)-alkylsulfonyl, nitro, pentafluorosulfanyl, phenyl, (C5-C7)-heterocycle, CO—NR6R7, O—CO—NR6R7 or O—CO—(C1-C6)-alkylene-CO—O—(C1-C6)-alkyl;
R1 is identically or differently (C6-C10)-alkyl, (C6-C12)-cycloalkyl, Y-phenyl or Y-heterocycle or bicycle, where cycloalkyl, phenyl, heterocycle or bicycle are optionally substituted one or more times by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxy, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, mono-(C1-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (C1-C6)-alkyloxycarbonyl, (C1-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (C1-C6)-alkylsulfonyl, aminosulfonyl or nitro;
Y is —CH2—, which is optionally substituted once by fluorine, methyl or hydroxy;
R2 is hydrogen; or
R1 and R2 together with the nitrogen atom carrying them form a monocyclic, saturated 5- to 6-membered ring system or a bicyclic saturated or partly unsaturated 9- to 10-membered ring system, whose individual members of the ring systems are optionally replaced by one to three atoms or atomic groups from the series —CHR4-, —CR4R5-, —(C═R4)-, —NR4-, —O— or —S—, with the proviso that two units from the series —O— or —S— are not adjacent to each other;
R3 is hydrogen, (C1-C6)-alkyl or benzyl;
R4, R5 are identically or differently (C1-C6)-alkyl, halogen, trifluoromethyl, COOR3, (C3-C7)-cycloalkyl, phenyl or heterocycle; and
R6, R7 are identically or differently hydrogen, (C1-C6)-alkyl, phenyl, benzyl or (C3-C12)-cycloalkyl; or
a tautomer thereof or a physiologically tolerated salt thereof,
with the proviso that not more than one R is phenyl or (C5-C7)-heterocycle.

### Claim 3 (depends on 1)

The compound of the formulae I or II as claimed in claim 1, wherein:
X is identically or differently ═C(—R)— or ═N—, where not more than one X is ═N—;
R is identically or differently hydrogen, halogen, hydroxy, (C1-C6)-alkyl, trifluoromethyl, (C1-C3)-alkyloxy or amino;
R1 is identically or differently (C6-C10)-alkyl, (C6-C12)-cycloalkyl, Y-phenyl or Y-heterocycle, where cycloalkyl, phenyl, or heterocycle are optionally substituted one or more times by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxy, amino, trifluoromethyl or trifluoromethyloxy;
Y is —CH2—;
R2 is hydrogen; or
R1 and R2 together with the nitrogen atom carrying them form a monocyclic, saturated 5- to 6-membered ring system or a bicyclic saturated or partly unsaturated 9- to 10-membered ring system, whose individual members of the ring systems are optionally replaced by one to three atoms or atomic groups from the series —CHR4-, —CR4R5-, —(C═R4)-, —NR4-, —O— or —S—, with the proviso that two units from the series —O— or —S— are not adjacent to each other;
R3 is hydrogen, (C1-C6)-alkyl or benzyl; and
R4, R5 are identically or differently (C1-C6)-alkyl, halogen, trifluoromethyl, COOR3, (C3-C7)-cycloalkyl, phenyl or (C5-C7)-heterocycle; or
a tautomer thereof or a physiologically tolerated salt thereof.

### Claim 4 (depends on 1)

The compound of the formulae I or II as claimed in claim 1 wherein:
X is identically or differently ═C(—R)— or ═N—, where not more than one X is ═N—;
R is identically or differently hydrogen, halogen, hydroxy, (C1-C6)-alkyl, trifluoromethyl, (C1-C3)-alkyloxy or amino;
R1 is identically or differently (C6-C10)-alkyl or Y-phenyl, which is optionally substituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy or trifluoromethyl;
Y is CH2;
R2 is hydrogen; or
R1 and R2 together with the nitrogen atom carrying them form a monocyclic, saturated 5- to 6-membered ring system, whose individual members are optionally replaced by one to three atoms or atomic groups from the series —CHR4-, —NR4-, —O— or —S—, with the proviso that two units from the series —O— or —S— are not adjacent to each other; and
R4 is (C1-C6)-alkyl, cyclopropyl, trifluoromethyl or phenyl; or
a tautomer thereof or a physiologically tolerated salt thereof.

### Claim 5 (depends on 1)

The compound of the formulae I or II as claimed in claim 1, wherein:
X is identically or differently ═C(—R)—.

### Claim 6 (depends on 1)

The compound of the formulae I or II as claimed in claim 1, wherein:
X in position 4, 5 and 6 is identically or differently ═C(—R)—, and in position 7 is ═N—.

### Claim 7 (depends on 1)

The compound of the formulae I or II as claimed in claim 1, wherein:
X in position 4, 5 and 7 is ═C(—R)— wherein R=hydrogen, and in position 6 is ═C(—R)— wherein R is not hydrogen.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 9 (depends on 2)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 2 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 10 (depends on 3)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 3 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 11 (depends on 4)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 4 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 12 (depends on 5)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 5 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 13 (depends on 6)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 6 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 14 (depends on 7)

A pharmaceutical composition comprising one or more compounds of the formulae I or II as claimed in claim 7 or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 15 (depends on 1)

A method for the treatment of disorders of fatty acid metabolism and glucose utilization disorders comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A method for the treatment of disorders in which insulin resistance is involved comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method for the treatment of diabetes mellitus and the sequelae associated therewith comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A method for the treatment of dyslipidemia and its sequelae comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A method for the treatment of conditions associated with the metabolic syndrome comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A method for the treatment of conditions associated with reduced HDL level comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method for the treatment of atherosclerotic disorders comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

A method for the treatment of disorders in which insulin resistance is involved comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of the formulae I or II as claimed in claim 1 or a pharmaceutically acceptable salt thereof in combination with at least one further active ingredient.

### Claim 23 (depends on 1)

A process for producing a medicament comprising one or more of the compounds of the formulae I or II as claimed in claim 1, which comprises mixing the latter with a pharmaceutically suitable carrier and converting this mixture into a form suitable for administration.

### Claim 24 (depends on 1)

A process for preparing compounds of the formulae I or II as claimed in claim 1, which comprises:
a) acylating an indazole derivative of the formula III with a carbamoyl chloride of the formula IV;
or
b) reacting in two stages initially with phosgene or an equivalent chosen from trichloromethyl chlorocarbonate, ditrichloromethyl carbonate or 4-nitrophenyl chloroformate and in a second step with an amine of formula V,
in which X, R1, R2 and R3 are as defined in claim 1,
and subsequently separating the compounds I and II.

### Claim 25 (depends on 1)

A process for preparing compounds of the formulae I or II as claimed in claim 1, wherein R2 is hydrogen, which comprises:
reacting an indazole derivative of the formula III with isocyanate of the formula VI: O═C═N—R1, and subsequently separating the compounds I and II.
